


Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Medicine

journal homepage: www.elsevier.com/locate/apjtm



Document heading doi: 10.1016/S1995-7645(14)60074-2

## Synergistic effects of ethnomedicinal plants of Apocynaceae family and antibiotics against clinical isolates of *Acinetobacter baumannii*

Sasitorn Chusri<sup>1,2\*</sup>, Thanyaluck Siriyong<sup>1</sup>, Pinanong Na-Phatthalung<sup>3</sup>, Supayang Piyawan Voravuthikunchai<sup>2,3</sup>

<sup>1</sup>Faculty of Traditional Thai Medicine, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand

<sup>2</sup>Natural Product Research Center of Excellence, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand

<sup>3</sup>Department of Microbiology, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand

### ARTICLE INFO

#### Article history:

Received 24 February 2014

Received in revised form 15 March 2014

Accepted 15 April 2014

Available online 20 June 2014

#### Keywords:

*Acinetobacter baumannii*

Antibacterial activity

Resistance modifying agents

Apocynaceae

Combination

Synergistic effect

### ABSTRACT

**Objective:** To investigate the efficacy of 17 ethnomedicinal plants belonging to Apocynaceae family used in combination with 16 conventional antibiotics against non-multidrug resistant-, multidrug resistant (MDR)-, and extensive drug resistant (XDR) *Acinetobacter baumannii* (*A. baumannii*). **Methods:** Antibacterial activity and resistance modifying ability of 272 combinations were determined by growth inhibition assays and further confirmed by time–kill assay. **Results:** Among the combinations of the antibiotics with Apocynaceae ethanol extracts on this pathogen, 15 (5%) had synergistic effects, 23 (8%) had partial synergistic effects and 234 (86%) had no effects. Synergistic activity was observed mostly when the Apocynaceae extracts were combined with rifampicin or cefazolin. Interestingly, 10 out of 17 combinations between the extracts and rifampicin displayed synergistic or partial synergistic behaviors. *Holarrhena antidysenterica* extract was additionally tested to restore rifampicin activity against clinical isolates of MDR and XDR *A. baumannii*. With respect to total or partial synergy, 70% was XDR *A. baumannii* isolates and 66% was MDR *A. baumannii* isolates. **Conclusions:** *Holarrhena antidysenterica* extract clearly demonstrated the ability to restore rifampicin activity against both *A. baumannii* ATCC19606 and clinically isolated *A. baumannii*. Additional studies examining its active principles as well as mechanisms of actions such as the effects on efflux pumps and outer membrane permeability alterations are recommended.

## 1. Introduction

Increasing prevalence of multidrug resistant (MDR) bacteria and limited treatment options have necessitated the discovery of new antibacterial and resistance modifying agents. Resistance modifying agents (RMAs) are compounds which potentiate the activity of an antibiotic against a resistant strain and may also target and inhibit MDR mechanisms[1]. An application of a RMA with a conventional antibiotic is well accepted. Augmentin<sup>®</sup> is an important

example which uses a combination of amoxicillin and a microbial-derived beta-lactamase inhibitor as a RMA (clavulanate)[2]. Recent experiments have additionally demonstrated that molecules capable of blocking the action of efflux pumps have the potential to circumvent antimicrobial resistance[3]. Stermitz *et al* reported for the first time the synergistic effect of a plant-derived ineffective antibacterial agent, berberine and a multidrug resistance pump inhibitor, 5'-methoxyhydnocarpin produced by *Berberis* species against *S. aureus*[4]. Furthermore, several plant-derived alkaloids and polyphenols such as reserpine, quinine, harmaline, piperine, epigallocatechin gallate, tellimagrandin I, and rugosin B have been demonstrated to act as efflux pump inhibitors for Gram positive pathogen[5]. Recently, we have demonstrated that *Holarrhena antidysenterica* (Linn) Wall. (Apocynaceae) possessed a

\*Corresponding author: Dr. Sasitorn Chusri, Faculty of Traditional Thai Medicine, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand.

E-mail: sasitorn.chu@psu.ac.th

Foundation project: This work was supported by the Thailand Research Fund (BRG 5580015, Fiscal year 2012–2014). Miss Pinanong Na-Phatthalung and Miss Thanyaluck Siriyong are funded by Natural Product Research Center of Excellence Postgraduate Scholarship.

remarkable RMA ability in combination with novobiocin against *Acinetobacter baumannii* (*A. baumannii*) ATCC 19606[6].

To our knowledge, there is no report on the RMA activity of other ethnomedicinal plants from the family Apocynaceae as well as relatively few studies have been carried out to evaluate RMA activities of plant-derived compounds on *A. baumannii*. Therefore, this study was aimed to investigate the RMA activity of medicinal plants belonging to the family Apocynaceae in combination with conventional antibiotics against *A. baumannii* ATCC 19606 and a collection of clinical *A. baumannii* isolates.

## 2. Materials and methods

### 2.1. Bacterial strains and culture condition

Clinically isolated *A. baumannii* isolates were obtained from Songklanakarin Hospital from pus ( $n=1$ ), blood ( $n=2$ ), sputum ( $n=5$ ), body fluid ( $n=4$ ), and urine ( $n=7$ ) samples of infected patients. *A. baumannii* ATCC 19606 was employed in this study as a quality control strain. The strains were cultured on tryptic soy agar (TSA) (Difco Laboratories, Detroit, MI) and incubated at 37 °C overnight. Colonies from the plates were grown in Mueller Hinton broth (MHB) (Difco Laboratories, Detroit, MI) at 37 °C for 18–24 h and adjusted to McFarland standards No. 0.5. The suspensions were further diluted with MHB to obtain inocula containing  $1 \times 10^6$  CFU/mL.

Susceptibility test was performed by the disk diffusion method according to Clinical and Laboratory Standard Institute (CLSI) recommendations[7]. MDR phenotypes were defined as isolates resistant to at least three different antimicrobial classes and the isolates resistant to all tested agents were classified as extensive drug resistant (XDR) phenotypes[8].

### 2.2. Medicinal plant materials and extraction

Seventeen selected plant species belonging to the Apocynaceae family were selected based on their potential use in folk medicine for treatments of diseases, or known to have antimicrobial activities as described in Table 1. The medicinal plants were purchased from medicinal herb retailers in Songkhla, Thailand and authenticated by a taxonomist, Dr. Katesarin Maneenoon and voucher specimens were deposited at the Faculty of Traditional Thai Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand. The samples were washed with distilled water and dried at 60 °C overnight. Ground plant material (100 g) was macerated with 95% (v/v) ethanol (500 mL) for 7 days at room temperature. After filtrations through a Whatman No. 1 paper, the filtrates were concentrated using a rotatory evaporator, and kept at 55 °C until they were completely dried. Yields (%; w/w) of each extracts were calculated as the ratio of the weight of the extract to the weight of the herb powder. A stock solution (200 mg/mL) was prepared by dissolving the dried extract in dimethylsulfoxide (DMSO) (Merck, Germany).

### 2.3. Resistant modifying ability of medicinal plant extracts

Intrinsic anti-*A. baumannii* ATCC19606 activities of the Apocynaceae extracts and a panel of selected antibiotics consisting of cell wall inhibitors (penicillin, oxacillin, ampicillin, imipenem, cefazolin, ceftazidime, and vancomycin), protein synthesis inhibitors (amikacin, gentamicin, streptomycin, fusidic acid, erythromycin, and tetracycline), DNA synthesis inhibitors (novobiocin and ciprofloxacin), and RNA synthesis inhibitors (rifampicin) were determined by growth inhibition assays as previously described[9]. Briefly, the culture, containing  $1 \times 10^6$  CFU/mL ( $100 \mu\text{L}$ ) was inoculated into a 96-well microtiter

**Table 1**

Medicinal properties and extraction yields of ethanol extracts of selected Apocynaceae ethnomedicinal plants.

Medicinal plants (Plant parts)	Medicinal properties	Extraction yield (%; w/w)
<i>Adenium obesum</i> (Forssk.) Roem. & Schult. (Leaves)	Anti-cancer activity[20]	1.85
<i>Allamanda cathartica</i> L. (Flowers)	Treating malaria and jaundice[21]	4.79
<i>Alstonia macrophylla</i> Wall. (Bark)	Body tonic and anti-fever agents[22]	2.76
<i>Alstonia scholaris</i> (L.) R.Br. (Bark)	Treating asthma and cardiac[23]	4.43
<i>Alyxia reinwardtii</i> BL. var. <i>lucida</i> Markgr. (Branch)	Antioxidant activity[24]	4.51
<i>Carissa spinarum</i> L. (Branch)	Wound healing activity[25]	3.50
<i>Catharanthus roseus</i> L. (Branch)	Used for treating cancers[26]	6.14
<i>Cerbera manghas</i> L. (Bark)	Anti-cancer activity[27]	12.20
<i>Cerbera odollam</i> Gaertn. (Bark)	Anti-cancer activity[28]	15.46
<i>Holarrhena antidysenterica</i> (L.) Wall. (Bark)	Antibacterial activity[29]	2.72
<i>Holarrhena curtisii</i> King & Gamble (Branch)	Leishmanicidal activities[30]	2.51
<i>Nerium oleander</i> L. (Branch)	Treating skin diseases[31]	4.52
<i>Plumeria obtusa</i> (Bark)	Treating skin diseases[32]	6.75
<i>Plumeria rubra</i> L. (Bark)	Antibacterial activity[33]	7.52
<i>Rauwolfia serpentina</i> (L.) Benth. ex Kurz (Root)	Antibacterial activity[34]	1.78
<i>Thevetia peruviana</i> (Pers.) K. (Bark)	Antidiarrhoeal and antimicrobial activities[35]	11.66
<i>Wrightia tomentosa</i> Roem. & Schult. (Branch)	Antibacterial activity[36]	2.75

plate containing 50  $\mu$  L of the extract (1 000  $\mu$  g/mL) or the antibiotic and 50  $\mu$  L of MHB. The antibiotics were purchased from Becton Dickinson Microbiology Systems (Sparks, MD, USA), Difco (Detroit, MI, USA) or made using the laboratory collection of antibiotics.

The intrinsic antibacterial activity was exhibited as the percentage of growth inhibition (GI) after incubation at 37 °C for 18 h and calculated from the following equation:

$$GI (\%) = (OD_{\text{control}} - OD_{\text{test}}) / OD_{\text{control}} \times 100. \quad (1)$$

where,  $OD_{\text{control}}$  is optical density (OD) 620 nm of bacteria culture in MHB supplemented with 1% (v/v) DMSO as a positive control and  $OD_{\text{test}}$  is OD 620 nm of the bacterial culture in MHB supplemented with the tested agent. The  $OD_{\text{test}}$  of respective blanks having only the extract was subtracted to give the final  $OD_{\text{test}}$ .  $GI_A$  and  $GI_E$  represent the percentage inhibition of bacterial growth of the antibiotic and extract, respectively.

Resistance modifying ability of each extract was observed by adding of 50  $\mu$  L of the tested extract into the tested plate supplemented with the antibiotic instead of MHB. This biological activity was exhibited as the percentage of growth inhibition as well but calculated from the following equation: %Growth inhibition of the combination ( $GI_C$ ) =  $(OD_{\text{control}} - OD_{\text{test}}) / OD_{\text{control}} \times 100.$  (2)

where,  $OD_{\text{control}}$  is OD 620 nm of the positive control culture and  $OD_{\text{test}}$  is OD 620 nm of the bacterial culture in MHB supplemented with the extract in combination with the antibiotic.

The interpretation of the combination was classified as synergism when  $GI_C/GI_A$  and  $GI_C/GI_E$  ratios were  $\geq 2.0$ , partial synergism when  $1.5 \leq$  the ratios  $< 2.0$ , and no effect when the ratios  $< 1.5$ . Ellagic acid at 40  $\mu$  mol/L was included as a positive control RMA in combination with erythromycin, novobiocin, and rifampicin against *A. baumannii* ATCC19606.

The efficacy of combination therapy of the promising medicinal plants in combination with the antibiotics was additionally determined against 19 clinically isolated *A. baumannii* isolates using the growth inhibition assay as described above and further confirmed by a time–kill assay.

### 3. Results

In this present investigation, the growth inhibition assay was employed to develop another approach for combating *A. baumannii* infections using medicinal plants to potentiate the activity of antibiotics. Independently, 15 out of 17 tested ethanol extracts at concentration of 1 000  $\mu$  g/mL displayed low inherent anti-*A. baumannii* activity (% of bacterial growth inhibition was less than 75%) (Table 2). Only *Alstonia macrophylla* and *Carissa spinarum* which completely inhibited the bacterial growth at this concentration possessed moderate antibacterial activity.

From 272 combinations tested between 17 medicinal plants and 16 antibiotics, 15 (5%) showed synergism, 23 (8%) had partial synergistic interaction, and 234 (86%) had no effect. Synergistic activity was observed mostly when the Apocynaceae extracts were combined with rifampicin or cefazolin against *A. baumannii* ATCC19606. Synergistic behaviors were displayed in cefazolin in combination with *Alstonia scholaris*, *Cerbera odollam*, *Holarrhena antidysenterica*, *Nerium oleander*, or *Thevetia peruwiana* or rifampicin in combination with *Adenium obesum*, *Holarrhena antidysenterica*, *Plumeria obtusa*, *Thevetia peruwiana*, or *Wrightia pubescens* (Table 3).

The ability of a representative effective resistance modifier, *Holarrhena antidysenterica* to potentiate the antibacterial activity of rifampicin against clinically isolated *A. baumannii* was additionally evaluated to explore the potential of developing a promising RMA (Table 4). The interaction between the ethanol extract and rifampicin was synergistic and partially synergistic in 8 (42.1%) and 3 (15.8%) isolates of *A. baumannii* tested, respectively. With respect to total or partial synergy, 70%, 66%, and 33% of the isolates were XDR *A. baumannii*, MDR *A. baumannii*, and non-MRD *A. baumannii*, respectively.

The synergistic effect of this combination was further confirmed by time–kill assay as illustrated in Figure 1. At the tested concentration, the extract exhibited no antibacterial potencies, but it was shown to be a powerful RMA in combination with rifampicin against *A. baumannii* ATCC 19606, non-MDR *A. baumannii*, and XDR *A. baumannii*.

**Table 2**

Intrinsic anti-*Acinetobacter* activity<sup>a</sup> of Apocynaceae ethnomedicinal plants.

Bacterial growth inhibition (%) <sup>b</sup>	No. of Apocynaceae (Plant species)
0–25	3 ( <i>Allamanda cathartica</i> ; <i>Cerbera manghus</i> ; <i>Thevetia peruwiana</i> )
26–49	8 ( <i>Adenium obesum</i> ; <i>Catharanthus roseus</i> ; <i>Holarrhena antidysenterica</i> ; <i>Holarrhena curtisii</i> ; <i>Nerium oleander</i> ; <i>Plumeria obtusa</i> ; <i>Plumeria rubra</i> ; <i>Wrightia pubescens</i> )
50–75	4 ( <i>Alstonia scholaris</i> ; <i>Alyxia reinwardtii</i> ; <i>Cerbera odollam</i> ; <i>Rauwolfia serpentine</i> )
76–100	2 ( <i>Alstonia macrophylla</i> ; <i>Carissa spinarum</i> )

<sup>a</sup>An antibacterial activity of phytochemicals is considered to be significant if MIC values are below 100  $\mu$  g/mL for crude extract and 10  $\mu$  g/mL for pure compounds[37].

<sup>b</sup>The percentage inhibition of bacterial growth was calculated by using the equation:

Bacterial growth inhibition (%) =  $(OD_{\text{control}} - OD_{\text{test}}) / OD_{\text{control}} \times 100$ . Where,  $OD_{\text{control}}$  represents the optical density at 620 nm of the control culture in MHB containing 1% (v/v) DMSO,  $OD_{\text{test}}$  represents the optical density at 620 nm of the culture in MHB containing 1 mg/mL of the ethanol extract. The  $OD_{\text{test}}$  of respective blanks having only the extract was subtracted to give the final  $OD_{\text{test}}$ .


**Table 3**Resistance modifying ability of Apocynaceae ethanol extracts in combination with selected antibiotics against *Acinetobacter baumannii* ATCC 19606.

Plant species	Number of synergy or partial synergy interactions [Antibiotics <sup>a</sup> ; (GI <sub>C</sub> :GI <sub>A</sub> /GI <sub>C</sub> :GI <sub>E</sub> ) <sup>b</sup> ]	
	Synergy <sup>c</sup>	Partial synergy <sup>c</sup>
<i>Adenium obesum</i>	1 RIF (2.8/2.0)	3 MEM (1.8/4.6), GEN (1.5/1.7), ERY (1.5/4.9)
<i>Allamanda cathartica</i>	0 –	1 FUS (1.7/3.3)
<i>Alstonia macrophylla</i>	0 –	0 –
<i>Alstonia scholaris</i>	1 KZ (21.6/7.9)	0 –
<i>Alyxia reinwardtii</i>	0 –	2 KZ (17.8/1.5), RIF (2.6/1.5)
<i>Catharanthus roseus</i>	0 –	1 STR (1.8/22.0)
<i>Carissa spinarum</i>	0 –	0 –
<i>Cerbera manghus</i>	3 MEM (3.5/4.7), GEN (4.2/2.6), ERY (2.4/4.3)	2 AMP (1.7/3.6), RIF (4.7/1.8)
<i>Cerbera odollam</i>	1 KZ (21.4/3.5)	5 PEN(2.4/1.9), OXA (2.2/1.9), AMP (2.3/1.7), VAN (2.7/1.5), RIF (2.0/1.9)
<i>Holarrhena antidysenterica</i>	3 KZ (21.4/3.5), STR (3.9/9.5), RIF (2.7/3.0)	0 –
<i>Holarrhena curtisii</i>	0 –	1 KZ (11.9/1.6)
<i>Nerium oleander</i>	1 KZ (15.7/2.7)	1 RIF (1.7/2.0)
<i>Plumeria obtusa</i>	1 RIF (2.0/4.2)	0 –
<i>Plumeria rubra</i>	0 –	2 GEN (1.6/2.3), RIF (1.7/1.5)
<i>Rawolfia serpentin</i>	0 –	0 –
<i>Spirolobium cambodianum</i>	0 –	0 –
<i>Thevetia peruwiana</i>	3 KZ (21.1/18.4), FUS (2.2/2.3), RIF (2.1/6.2)	0 –
<i>Wrightia pubescens</i>	1 RIF (2.0/2.1)	5 MEM (1.7/6.4), KZ (1.8/35.3), GEN (1.8/3.1), STR (1.9/24.0), ERY (1.9/9.0),

<sup>a</sup>PEN=Penicillin G; OXA=Oxacillin; AMP=Ampicillin; MEM=Meropenem; KZ=Cephazolin; VAN=Vancomycin; GEN=Gentamicin; STR=Streptomycin; FUS=Fusidic acid; ERY=Erythromycin; RIF=Rifampicin.

<sup>b</sup>GI<sub>C</sub> represents the percentage inhibition of bacterial growth of tested antibiotics in combination with the extracts. GI<sub>A</sub> and GI<sub>E</sub> represent the percentage inhibition of bacterial growth of the antibiotics and the extracts, respectively.

<sup>c</sup>Combinations were classified as synergistic effects if both GI<sub>C</sub>:GI<sub>A</sub> and GI<sub>C</sub>:GI<sub>E</sub> ratios were  $\geq 2.0$ , partially synergistic effects if  $1.5 \leq$  the ratios  $< 2.0$ , indifferent effects if the ratios were  $< 1.5$ .



**Figure 1.** Time–kill activities of *Holarrhena antidysenterica* (HA; 125  $\mu$ g/mL), rifampicin (Ri; 1/4 MIC), novobiocin (No; 1/4 MIC), the combination of *Holarrhena antidysenterica* and rifampicin (Ri+HA), and the combination of *Holarrhena antidysenterica* and novobiocin (No+HA) against *Acinetobacter baumannii* ATCC 19606 (A), non–MDR *A. baumannii* (B), and XDR *A. baumannii* (C). Minimum inhibitory concentrations of Ri and No against *A. baumannii* ATCC 19606, non–MDR *A. baumannii*, and XDR *A. baumannii* were 0.63 and 6.25, 5.00 and 25.00, and 1.25 and 6.25  $\mu$ g/mL, respectively.

#### 4. Discussion

Uses of rifampicin in combination with colistin have been studied for the treatment of MDR *A. baumannii* infections. Both *in vitro* studies and clinical studies were employed to recommend the safety and clinical effectiveness of rifampicin in combination with colistin against this pathogen<sup>[10–13]</sup>. It was suggested that colistin probably causes rapid permeabilization of the outer membrane, which enhances penetration and activity of rifampicin. Similarly, plant–derived compounds that act as permeabilizers such as

coriander oil (*Coriandrum sativum*)<sup>[14]</sup>, geraniol (*Helichrysum italicum*)<sup>[15]</sup>, and [6]–dehydrogingerdione and [10]–gingerol (*Zingiber officinale*)<sup>[16]</sup> have been shown to reduce the resistance of *A. baumannii* to other antibiotics. Even though antibacterial activity of *Holarrhena antidysenterica* and its constituents have been reported, there is to our knowledge no published scientific literature of RMA activity on rifampicin of this plant or its constituents.

Rifampicin resistance in *A. baumannii* is related to the synergistic interaction between modifications of antibiotic permeability, enzymatic modification by rifampicin

**Table 4**

Effects of *Holarrhena antidysenterica* ethanol extract (HA; 125  $\mu$ g/mL) as a resistant modifying agent for rifampicin (Ri; 0.5  $\mu$ g/mL) against clinically isolated *A. baumannii*.

MDR- <i>A. baumannii</i> isolates (Sources) <sup>a</sup>	Antibiogram profile <sup>b</sup>	GI (%) <sup>c</sup> in the presence of		GI <sub>C</sub> :GI <sub>A</sub> /GI <sub>C</sub> :GI <sub>E</sub> <sup>d</sup>
		Ri (0.5 $\mu$ g/mL)	HA (125 $\mu$ g/mL)	
NPRC AB002 (BF)	SRISRSSSSS	13.2±1.3	13.6±1.1	1.0/1.0
NPRC AB003 (S)	RRRRRRRRSR	40.8±1.4	35.7±1.0	2.5/2.9
NPRC AB004 (U)	SRISISSSSS	89.2±1.2	2.0±1.7	1.1/7.0
NPRC AB005 (U)	RRRRR-RSIS	19.2±0.6	-21.0±1.5	1.8/1.7
NPRC AB010 (B)	RRRRRRRRSR	30.7±1.8	35.5±3.7	1.6/1.4
NPRC AB011 (U)	RRRRRRRRIR	37.2±0.5	37.3±1.3	1.0/1.0
NPRC AB013 (B)	RRRRRRRRRR	17.8±2.6	37.9±2.9	4.8/2.3
NPRC AB014 (U)	SRRSR-SRIR	19.0±4.1	22.0±2.8	4.4/3.8
NPRC AB015 (U)	RRRRR-RRRR	25.3±0.7	23.0±1.4	2.1/2.3
NPRC AB016 (U)	SRRSRSSSSS	51.8±1.9	23.8±5.0	1.2/2.7
NPRC AB017 (BF)	RRRRRRRRRR	64.7±0.9	56.1±1.1	1.6/1.9
NPRC AB018 (S)	RRRRRRRRRR	32.8±2.4	34.8±2.0	2.0/1.9
NPRC AB019 (S)	RRRRRRRRRR	33.3±0.8	30.0±0.8	2.3/2.5
NPRC AB021 (S)	SRISR-SRSR	40.7±2.8	27.5±1.6	2.1/3.2
NPRC AB022 (U)	RRRRRRRRRR	18.1±1.6	39.2±1.1	2.1/0.4
NPRC AB024 (BF)	-RRR-R-R--	57.9±0.9	27.8±1.9	1.8/3.7
NPRC AB026 (S)	RRRRRRRRSR	34.4±0.7	37.3±0.8	4.7/3.0
NPRC AB028 (BF)	RRRRRRRRIR	35.9±1.5	28.8±1.0	2.1/2.6
NPRC AB029 (P)	SRSSSSSSSS	17.4±4.8	27.5±3.8	1.4/8.7

<sup>a</sup>Clinically isolated *A. baumannii* were obtained from pus (P), blood (B), sputum (S), body fluid (BF), and urine (U) samples of infected patients.

<sup>b</sup>The antibiogram profile is the susceptibility results for amikacin, ampicillin, cefotaxime, ceftazolin, cefuroxime, ciprofloxacin, gentamicin, imipenem, cephoperazon/sulbactam, and meropenem.

<sup>c</sup>GI represents the percentage inhibition of bacterial growth of the tested compounds.

<sup>d</sup>Combinations were classified as synergistic effects (GI<sub>C</sub>:GI<sub>A</sub> and GI<sub>C</sub>:GI<sub>E</sub> ratios  $\leq 2.0$ ), partially synergetic effects ( $1.5 \leq$  GI<sub>C</sub>:GI<sub>A</sub> and GI<sub>C</sub>:GI<sub>E</sub> ratios  $< 2.0$ ), indifferent effects (GI<sub>C</sub>:GI<sub>A</sub> and GI<sub>C</sub>:GI<sub>E</sub> ratios  $< 1.5$ ). GI<sub>A</sub>, GI<sub>E</sub>, and GI<sub>C</sub> represent the percentage inhibition of bacterial growth of Ri, HA, and the Ri+HA combination, respectively.

ADP-ribosyl-transferase (arr-2), or mutation in rpoB<sup>[17-19]</sup>. A recent finding by Giannouli *et al* proposed that the combined treatment with colistin/rifampicin versus colistin alone were evident only in *A. baumannii* strains with no chromosomal mutations in RNA polymerase  $\beta$ -subunit rpoB target gene<sup>[11]</sup>. Interestingly, phenylalanine arginine  $\beta$ -naphthylamide (PA  $\beta$  N), an efflux pump inhibitor, reduced the minimum inhibitory concentration of rifampicin at 256  $\mu$ g/mL by approximately 30-fold in *A. baumannii* isolate that showed no mutation in the rpoB target gene<sup>[11]</sup>.

The present results indicate that the ethanol extract of *Holarrhena antidysenterica* is a promising resistance modifying agent for rifampicin against *A. baumannii*, due to its synergistic effect in combination with rifampicin against both *A. baumannii* ATCC19606 and clinically isolated *A. baumannii*. The findings may lead to development of an effective alternative treatment in combating the antimicrobial resistance in *A. baumannii*. Therefore, the mechanisms of action of this combination as well as the active constituents of *Holarrhena antidysenterica* should be further investigated.

### Acknowledgments

This work was supported by the Thailand Research Fund (BRG 5580015, Fiscal year 2012–2014). Miss Pinanong Na-

Phatthalung and Miss Thanyaluck Siriyong are funded by Natural Product Research Center of Excellence Postgraduate Scholarship. We are thankful to Miss Stefania Vignotto for editing the manuscript.

### Conflict of interest statement

We declare that we have no conflict of interest.

### References

- [1] Gibbons S. Anti-staphylococcal plant natural products. *Nat Prod Rep* 2004; **21**: 263–277.
- [2] Moreillon P. The efficacy of amoxicillin/clavulanate (Augmentin) in the treatment of severe staphylococcal infections. *J Chemother* 1994; **6**: 51–57.
- [3] Stavri M, Piddock LJ, Gibbons S. Bacterial efflux pump inhibitors from natural sources. *J Antimicrob Chemother* 2007; **59**: 1247–1260.
- [4] Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydrnocarpin, a multidrug pump inhibitor. *Proc Natl Acad Sci USA* 2000; **97**: 1433–1437.
- [5] Hemaiswarya S, Kruthiventi AK, Doble M. Synergism between natural products and antibiotics against infectious diseases. *Phytomedicine* 2008; **15**: 639–652.

- [6] Phatthalung PN, Chusri S, Voravuthikunchai SP. Thai ethnomedicinal plants as resistant modifying agents for combating *Acinetobacter baumannii* infections. *BMC Complement Altern Med* 2012; **12**: 56.
- [7] Clinical and Laboratory Standards Institute (CLSI) 2009. M02–A10–Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard–Tenth Edition. Clinical and Laboratory Standards Institute. USA: Wayne.
- [8] Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram–negative bacilli: need for international harmonization in terminology. *Clin Infect Dis* 2008; **46**: 1121–1122.
- [9] Chusri S, Villanueva I, Voravuthikunchai SP, Davies J. Enhancing antibiotic activity: a strategy to control *Acinetobacter* infections. *J Antimicrob Chemother* 2009; **64**: 1203–1211.
- [10] Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug–resistant *Acinetobacter baumannii* infections. *J Antimicrob Chemother* 2008; **61**: 417–420.
- [11] Giannouli M, Di Popolo A, Durante–Mangoni E, Bernardo M, Cuccurullo S, Amato G, et al. Molecular epidemiology and mechanisms of rifampicin resistance in *Acinetobacter baumannii* isolates from Italy. *Int J Antimicrob Agents* 2012; **39**: 58–63.
- [12] Motaouakkil S, Charra B, Hachimi A, Nejmi H, Benslama A, Elmdaghri N, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant *Acinetobacter baumannii*. *J Infect* 2006; **53**: 274–278.
- [13] Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, et al. Combined colistin and rifampicin therapy for carbapenem–resistant *Acinetobacter baumannii* infections: clinical outcome and adverse events. *Clin Microbiol Infect* 2005; **11**: 682–683.
- [14] Duarte A, Ferreira S, Silva F, Domingues FC. Synergistic activity of coriander oil and conventional antibiotics against *Acinetobacter baumannii*. *Phytomedicine* 2012; **19**: 236–238.
- [15] Lorenzi V, Muselli A, Bernardini AF, Berti L, Pages JM, Amaral L, et al. Geraniol restores antibiotic activities against multidrug–resistant isolates from gram–negative species. *Antimicrob Agents Chemother* 2009; **53**: 2209–2211.
- [16] Wang HM, Chen CY, Chen HA, Huang WC, Lin WR, Chen TC, et al. *Zingiber officinale* (ginger) compounds have tetracycline–resistance modifying effects against clinical extensively drug–resistant *Acinetobacter baumannii*. *Phytother Res* 2010; **24**: 1825–1830.
- [17] Houang ET, Chu YW, Lo WS, Chu KY, Cheng AF. Epidemiology of rifampin ADP–ribosyltransferase (arr–2) and metallo–beta–lactamase (blaIMP–4) gene cassettes in class 1 integrons in *Acinetobacter* strains isolated from blood cultures in 1997 to 2000. *Antimicrob Agents Chemother* 2003; **47**: 1382–1390.
- [18] Thapa B, Tribuddharat C, Rugdeekha S, Techachaiwiwat W, Srfuengfung S, Dhiraputra C. Rifampin resistance in carbapenem–resistant *Acinetobacter baumannii* in Siriraj Hospital, Thailand. *Nepal Med Coll J* 2009; **11**: 232–237.
- [19] Tupin A, Gualtieri M, Roquet–Baneres F, Morichaud Z, Brodolin K, Leonetti JP. Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns. *Int J Antimicrob Agents* 2010; **35**: 519–523.
- [20] Almhedar H, Abdallah HM, Osman AM, Abdel–Sattar EA. *In vitro* cytotoxic screening of selected Saudi medicinal plants. *J Nat Med* 2012; **66**: 406–412.
- [21] Nayak S, Nalabothu P, Sandiford S, Bhogadi V, Adogwa A. Evaluation of wound healing activity of *Allamanda cathartica*. L. and *Laurus nobilis*. L. extracts on rats. *BMC Complement Altern Med* 2006; **6**: 12.
- [22] Changwichit K, Khorana N, Suwanborirux K, Waranuch N, Limpeanchob N, Wisuitiprot W, et al. Bisindole alkaloids and secoiridoids from *Alstonia macrophylla* Wall. ex G. Don. *Fitoterapia* 2011; **82**: 798–804.
- [23] Shang JH, Cai XH, Zhao YL, Feng T, Luo XD. Pharmacological evaluation of *Alstonia scholaris*: anti–tussive, anti–asthmatic and expectorant activities. *J Ethnopharmacol* 2010; **129**: 293–298.
- [24] Jurairat R, Jirapast S, Santi TP. Chemical constituents and antioxidant activity from the stems of *Alyxia reinwardtii*. *Rec Nat Prod* 2012; **6**: 288–291.
- [25] Sanwal R, Chaudhary AK. Wound healing and antimicrobial potential of *Carissa spinarum* Linn. in albino mice. *J Ethnopharmacol* 2011; **135**: 792–796.
- [26] Peebles CA, Hong SB, Gibson SI, Shanks JV, San KY. Effects of terpenoid precursor feeding on *Catharanthus roseus* hairy roots over–expressing the alpha or the alpha and beta subunits of anthranilate synthase. *Biotechnol Bioeng* 2006; **93**: 534–540.
- [27] Cheenpracha S, Karalai C, Rat APY, Ponglimanont C, Chantrapromma K. New cytotoxic cardenolide glycoside from the seeds of *Cerbera manghas*. *Chem Pharm Bull (Tokyo)* 2004; **52**: 1023–1025.
- [28] Laphookhieo S, Cheenpracha S, Karalai C, Chantrapromma S, RataPa Y, Ponglimanont C, et al. Cytotoxic cardenolide glycoside from the seeds of *Cerbera odollam*. *Phytochemistry* 2004; **65**: 507–510.
- [29] Kavitha D, Shilpa PN, Devaraj SN. Antibacterial and antidiarrhoeal effects of alkaloids of *Holarrhena antidysenterica* WALL. *Indian J Exp Biol* 2004; **42**: 589–594.
- [30] Kam TS, Sim KM, Koyano T, Toyoshima M, Hayashi M, Komiya K. Cytotoxic and leishmanicidal aminoglycoesteroids and aminosteroids from *Holarrhena curtisii*. *J Nat Prod* 1998; **61**: 1332–1336.
- [31] Bhuvaneshwari L, Arthy E, Anitha C, Dhanabalan K, Meena M. Phytochemical analysis and antibacterial activity of *Nerium oleander*. *Anc Sci Life* 2007; **26**: 24–28.
- [32] Saleem M, Akhtar N, Riaz N, Ali MS, Jabbar A. Isolation and characterization of secondary metabolites from *Plumeria obtusa*. *J Asian Nat Prod Res* 2011; **13**: 1122–1127.
- [33] Hamburger MO, Cordell GA, Ruangrunsi N. Traditional medicinal plants of Thailand. XVII. Biologically active constituents of *Plumeria rubra*. *J Ethnopharmacol* 1991; **33**: 289–292.
- [34] Rasheed A, Avinash Kumar Reddy G, Mohanalakshmi S, Ashok Kumar CK. Formulation and comparative evaluation of poly herbal anti–acne face wash gels. *Pharm Biol* 2011; **49**: 771–774.
- [35] Kareru PG, Keriko JM, Kenji GM, Thiong’o GT, Gachanja AN, Mukiira HN. Antimicrobial activities of skincare preparations from plant extracts. *Afr J Tradit Complement Altern Med* 2010; **7**: 214–218.
- [36] Nagarajan K, Mazumder A, Ghosh LK. Comparative anti–microbial evaluation studies of the extracts and isolates of leaves and bark of *Wrightia tomentosa*. *Anc Sci Life* 2006; **26**: 12–18.
- [37] Kuete V. Potential of Cameroonian plants and derived products against microbial infections: a review. *Planta Med* 2010; **76**: 1479–1491.